NFJ Investment Group LLC Acquires 404,266 Shares of Pfizer Inc. (NYSE:PFE)

NFJ Investment Group LLC increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 105.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 788,837 shares of the biopharmaceutical company's stock after purchasing an additional 404,266 shares during the quarter. NFJ Investment Group LLC's holdings in Pfizer were worth $20,928,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. PSI Advisors LLC raised its holdings in Pfizer by 1.4% during the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock valued at $738,000 after buying an additional 385 shares in the last quarter. Patriot Financial Group Insurance Agency LLC increased its holdings in shares of Pfizer by 1.0% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 38,706 shares of the biopharmaceutical company's stock valued at $1,027,000 after acquiring an additional 391 shares during the last quarter. D Orazio & Associates Inc. raised its stake in shares of Pfizer by 5.5% in the 4th quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company's stock valued at $200,000 after acquiring an additional 391 shares in the last quarter. Lipe & Dalton lifted its holdings in Pfizer by 17.7% in the 4th quarter. Lipe & Dalton now owns 2,659 shares of the biopharmaceutical company's stock worth $71,000 after purchasing an additional 400 shares during the last quarter. Finally, Oliver Luxxe Assets LLC boosted its position in Pfizer by 2.2% during the fourth quarter. Oliver Luxxe Assets LLC now owns 18,811 shares of the biopharmaceutical company's stock worth $499,000 after purchasing an additional 401 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of PFE stock traded up $0.09 during mid-day trading on Friday, reaching $22.13. The company's stock had a trading volume of 53,854,504 shares, compared to its average volume of 40,486,092. The firm's 50-day moving average is $24.88 and its two-hundred day moving average is $26.15. The company has a market cap of $125.50 billion, a P/E ratio of 15.69, a PEG ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the prior year, the business posted $0.10 earnings per share. The company's quarterly revenue was up 24.7% compared to the same quarter last year. On average, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the company's stock in a transaction on Thursday, February 13th. The stock was purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have recently commented on PFE shares. Guggenheim reissued a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Citigroup restated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Finally, UBS Group decreased their target price on Pfizer from $28.00 to $24.00 and set a "neutral" rating for the company in a research note on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of "Moderate Buy" and an average target price of $31.07.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.